CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 152 enrolled
Drug / intervention
Apremilast +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03930186
NCT03930186Phase 3Completed
CompareCT.gov

A Phase 3b, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy

Amgen·interventional·Posted Apr 29, 2019·Updated Jan 20, 2022

In Brief

A Phase 3 clinical trial evaluating Apremilast and Topical Therapy for Plaque Psoriasis. Completed, enrolled 152 participants across 56 sites in 2 countries.

Detailed Summary

The primary objective of the study is to assess the efficacy and safety of the combination of apremilast plus topical therapies for the treatment of adults with plaque psoriasis who have not achieved an adequate response with topicals alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesGermany, Japan
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 29, 2019
Enrollment StartJun 17, 2019
Primary CompletionMay 8, 2020
Study CompletionSep 25, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.2 years ago

Interventions

Apremilastdrug

Tablets for oral administration

Topical Therapydrug

Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.